Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATI-1701
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Appili Therapeutics
Deal Size : $1.2 million
Deal Type : Termination
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
Details : The termination allows Appili to refocus on advancing its pipeline of anti-infectives, including ATI-1701, a next-generation LA vaccine with a targeted, well-characterized mechanism of attenuation.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 30, 2025
Lead Product(s) : ATI-1701
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Appili Therapeutics
Deal Size : $1.2 million
Deal Type : Termination
Lead Product(s) : ATI-1701
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Aditxt Signs Amendment with Appili Therapeutics for September 30 Acquisition Close
Details : Aditxt will acquire Appili along with its pipeline, which includes the ATI-1701 vaccine. Currently, the vaccine is undergoing evaluation in preclinical trials for the treatment of tularemia.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : ATI-1701
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : ATI-1701
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
Details : Aditxt will acquire Appili and its pipeline, including ATI-1701, a vaccine in preclinical trials for tularemia treatment.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 04, 2024
Lead Product(s) : ATI-1701
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Evofem Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition of Evofem, Aditxt gains access to its first and only FDA-approved hormone-free contraceptive gel, Phexxi (lactic acid, citric acid, and potassium bitartrate).
Product Name : Phexxi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Evofem Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Cellvera
Deal Size : $10.0 million
Deal Type : Agreement
Details : Under the agreement, Aditxt expands its portfolio to include innovative therapies for infectious diseases by including Avigan (favipiravir), an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase.
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
April 20, 2023
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Cellvera
Deal Size : $10.0 million
Deal Type : Agreement
Lead Product(s) : ADI-100
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI™-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : ADI-100
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $20.0 million
Deal Type : Public Offering
Aditxt Announces Pricing of $20.0 Million Public Offering
Details : The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $20.0 million
Deal Type : Public Offering
Lead Product(s) : ADI-100
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 07, 2022
Lead Product(s) : ADI-100
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Cellvera
Deal Size : Undisclosed
Deal Type : Agreement
Details : Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious dise...
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 04, 2022
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Cellvera
Deal Size : Undisclosed
Deal Type : Agreement